Bernadka Dubicka

Bernadka Dubicka

Auto-generated profile, based on publicly available information

Bernadka Dubicka

Hull and York Medical School, University of York, York, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
PWPaul O. Wilkinson
Paul O. Wilkinson
RKRaphael Kelvin
Raphael Kelvin
CRChris Roberts
Chris Roberts
BDBernadka Dubicka
Bernadka Dubicka
IGIan Goodyer
Ian Goodyer

7 June 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
IGIan Goodyer
Ian Goodyer
BDBernadka Dubicka
Bernadka Dubicka
PWPaul Wilkinson
Paul Wilkinson
RKRaphael Kelvin
Raphael Kelvin
CRChris Roberts
Chris Roberts
RHRichard Harrington
Richard Harrington
Objective To determine whether a combination of a selective serotonin reuptake inhibitor (SSRIs) and cognitive behaviour therapy (CBT) together with clinical care is more effective in the short term than an SSRI and clinical care alone in adolescents with moderate to severe major depression.Design Pragmatic randomised controlled superiority trial.Setting 6 outpatient clinics in Manchester and Cambridge.Participants 208 adolescents, aged 11-17, with moderate to severe major or probable major depression who had not responded to a brief initial intervention. Adolescents with suicidality, depressive psychosis, or conduct disorder were included.Interventions 103 adolescents received an SSRI and routine care; 105 received an SSRI, routine care, and CBT. The trial lasted 12 weeks, followed by a 16 week maintenance phase.Main outcome measures Change in score on the Health of the Nation outcome scales for children and adolescents (primary outcome) from baseline with 12 weeks as the primary and 28 weeks as the follow-up end point. Secondary measures were change in scores on the mood and feelings questionnaire, the revised children's depression rating scale, the children's global assessment scale, and the clinical global impression improvement scale.Results At 12 weeks the treatment effect for the primary outcome was −0.64 (95% confidence interval −2.54 to 1.26, P=0.50). In a longitudinal analysis, there was no difference in effectiveness of treatment for the primary (average treatment effect 0.001, −1.52 to 1.52, P=0.99) or secondary outcome measures. On average there was a decrease in suicidal thoughts and self harm. There was no evidence of a protective effect of cognitive behaviour therapy on suicidal thinking or action. By 28 weeks, 57% were much or very much improved with 20% remaining unimproved.Conclusions For adolescents with moderate to severe major depression there is no evidence that the combination of CBT plus an SSRI in the presence of routine clinical care contributes to an improved outcome by 28 weeks compared with the provision of routine clinical care plus an SSRI alone.Trial registration Current Controlled Trials ISRCNT 83809224.

13 November 2019 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
ADAndrea Danese
Andrea Danese
PSPatrick Smith
Patrick Smith
PCPrathiba Chitsabesan
Prathiba Chitsabesan
BDBernadka Dubicka
Bernadka Dubicka
Summary: The mental health of children and young people can be disproportionally affected and easily overlooked in the context of emergencies and disasters. Child and adolescent mental health services can contribute greatly to emergency preparedness, resilience and response and, ultimately, mitigate harmful effects on the most vulnerable members of society.

1 December 1999 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
JAJennifer C. Ablow
Jennifer C. Ablow
JMJeffrey R. Measelle
Jeffrey R. Measelle
HKHelena C. Kraemer
Helena C. Kraemer
RHRichard Harrington
Richard Harrington
JLJoan Luby
Joan Luby
DKDavid J. Kupfer
David J. Kupfer
Three sites collaborated to evaluate the reliability and validity of 2 measures, developed in tandem to assess symptomatology and impairment in 4- to 8-year-old children: the Berkeley Puppet Interview Symptomatology Scales (BPI-S) and the Health and Behavior Questionnaire (HBQ). In this case-control study, mothers, teachers, and children reported on multiple dimensions of children's mental health for 120 children (67 community and 53 clinic-referred children). The BPI-S and the parent and teacher versions of the HBQ demonstrated strong test-retest reliability and discriminant validity on a majority of symptom scales. Medium to strong effect sizes (Cohen d) indicated that children in the clinic-referred group were viewed by all 3 informants as experiencing significantly higher levels of symptomatology than nonreferred, community children. The availability of a set of multi-informant instruments that are psychometrically sound, developed in tandem, and developmentally appropriate for young children will enhance researchers' ability to investigate and understand symptomatology or the emergence of symptomatology in middle childhood.

13 July 2011 in Trials
Verified
Journal Article
Open access
PDF file
IGIan M Goodyer
Ian M Goodyer
STSonya Tsancheva
Sonya Tsancheva
SBSarah Byford
Sarah Byford
BDBernadka Dubicka
Bernadka Dubicka
JHJonathan Hill
Jonathan Hill
PFPeter Fonagy
Peter Fonagy
Up to 70% of adolescents with moderate to severe unipolar major depression respond to psychological treatment plus Fluoxetine (20-50 mg) with symptom reduction and improved social function reported by 24 weeks after beginning treatment. Around 20% of non responders appear treatment resistant and 30% of responders relapse within 2 years. The specific efficacy of different psychological therapies and the moderators and mediators that influence risk for relapse are unclear. The cost-effectiveness and safety of psychological treatments remain poorly evaluated. Improving Mood with Psychoanalytic and Cognitive Therapies, the IMPACT Study, will determine whether Cognitive Behavioural Therapy or Short Term Psychoanalytic Therapy is superior in reducing relapse compared with Specialist Clinical Care. The study is a multicentre pragmatic effectiveness superiority randomised clinical trial: Cognitive Behavioural Therapy consists of 20 sessions over 30 weeks, Short Term Psychoanalytic Psychotherapy 30 sessions over 30 weeks and Specialist Clinical Care 12 sessions over 20 weeks. We will recruit 540 patients with 180 randomised to each arm. Patients will be reassessed at 6, 12, 36, 52 and 86 weeks. Methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of assessments with control for rater shift, research assessors independent of treatment team and blind to randomization, analysis by intention to treat, data management using remote data entry, measures of quality assurance, advanced statistical analysis, manualised treatment protocols, checks of adherence and competence of therapists and assessment of cost-effectiveness. We will also determine whether time to recovery and/or relapse are moderated by variations in brain structure and function and selected genetic and hormone biomarkers taken at entry. The objective of this clinical trial is to determine whether there are specific effects of specialist psychotherapy that reduce relapse in unipolar major depression in adolescents and thereby costs of treatment to society. We also anticipate being able to utilise psychotherapy experience, neuroimaging, genetic and hormone measures to reveal what techniques and their protocols may work best for which patients. Current Controlled Trials ISRCTN83033550

1 November 2006 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
BDBernadka Dubicka
Bernadka Dubicka
SHSarah Hadley
Sarah Hadley
CRChristopher Roberts
Christopher Roberts
Background: Concern exists that antidepressants can cause suicidality in youths with depression.Aims: To determine the pooled risk of self-harm and suicidal behaviour from randomised trials of newer antidepressants.Method: A meta-analysis was carried out to calculate odds ratios for the combined data.Results: Self-harm or suicide-related events occurred in 71 of 1487 (4.8%) of depressed youths treated with antidepressants v. 38 of 1254 (3.0%) of those given placebo (fixed effects odds ratio 1.70, 95% CI 1.13–2.54, P=0.01). There was a trend for individual suicidal thoughts, attempts and self-harm to occur more often in youths taking antidepressants than in those given placebo, but none of these differences was statistically significant.Conclusions: Antidepressants may cause a small short-term risk of self-harm or suicidal events in children and adolescents with major depressive disorder.